PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma: A more recent trial investigating the efficacy and safety of the anti PD1 antibody geptanolimab in a larger PTCL cohort showed a 17.9% overall response rate (ORR) for the PTCL_NOS subset [68].